Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in Washington

ARLINGTON, Va., September 4, 2024 — The American Society for Radiation Oncology (ASTRO) announced today the seven studies to be highlighted in the 2024 ASTRO Annual Meeting press program.

Researchers will discuss their findings in news briefings held September 30 and October 1 at the Walter E. Washington Convention Center in Washington, D.C. and via live webcast. Reporters can register to attend the briefings and join the Annual Meeting virtually or in person in our press kit at www.astro.org/annualmeetingpress.

The news briefing schedule is as follows:

Monday, September 30, 10:00 a.m. Eastern time

• Abstract 1: “A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505),” presented by Matthew Poppe, MD, FASTRO, University of Utah Huntsman Cancer Institute

• LBA 01: “Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III randomized clinical trial of proton therapy vs IMRT for localized prostate cancer,” presented by Jason Efstathiou, MD, PhD, FASTRO, Massachusetts General Hospital

• LBA 02: “Concurrent chemoradiation +/- atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005,” presented by Kristin A. Higgins, MD, City of Hope Cancer Center Atlanta

• LBA 03: “Interim futility results of NRG-HN005, a randomized, phase II/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients,” presented by Sue Yom, MD, PhD, FASTRO, University of California, San Francisco

• Moderator: Sameer Keole, MD, FASTRO, Mayo Clinic, ASTRO President-elect

Tuesday, October 1, 9:00 a.m. Eastern time

• Abstract 2: “A prospective, phase II study of 177Lu-Dotatate in patients with surgery- and radiation-refractory meningioma: Results of the WHO grade II/III cohort,” presented by Kenneth Merrell, MD, Mayo Clinic Alix School of Medicine

• Abstract 150: “Evaluating neurocognitive recovery following stereotactic radiosurgery and whole brain radiation therapy: Insights from a pooled analysis of three phase III trials,” presented by Hua-Ren Ryan Cherng, MD, University of Maryland Medical Center

• Abstract 215: “Centering Black voices: Factors influencing a cancer patient’s decision to join a clinical trial,” presented by Charlyn Gomez, University of Maryland School of Medicine

• Moderator: Andrea K. Ng, MD, MPH, FASTRO, Dana-Farber/Brigham and Women’s Cancer Center, incoming ASTRO Education Council Vice Chair

ABOUT ASTRO

The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. Radiation therapy contributes to 40% of global cancer cures, and more than a million Americans receive radiation treatments for cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and follow us on social media.